Articles Archives - Page 302 of 715

ThursdayJan 27, 2022 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend

Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuse Well+Good says psychedelics “poised to change the course of mental health treatment” Cybin working to combine novel psychedelic molecules with controllable drug-delivery systems through proprietary deuterated process A USA Today article is touting psychedelics as the next big thing in mental health treatment (https://ibn.fm/3ZGGE). This forecast aligns perfectly with what Cybin (NEO: CYBN) (NYSE American: CYBN) has been working toward since the company started: a strategic psychedelics to therapeutics model that will transform the mental health space. “If you haven't heard about psychedelics being used as a treatment…

ThursdayJan 27, 2022 9:00 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Gains Full Cannabis Licensing to Rise in Michigan’s Developing Recreational Use Market

Multi-state cannabis operator Red White & Bloom Brands is developing opportunities strategically in sizable cannabis markets such as Michigan, Florida, Illinois, California, Arizona, Oklahoma and Massachusetts The company recently announced it has secured full licensing for manufacturing both medical and adult use cannabis products in Michigan, one of its key markets Red White & Bloom has closed on a lease assignment for a 15,000-square-foot manufacturing, processing and distribution facility in the state In Florida, Red White & Bloom settled a CAD$5.1 million debt at a favorable conversion price, granting the company an accounting gain of approximately CAD$2.3 million As Michigan…

WednesdayJan 26, 2022 12:15 pm

InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging on the Growing Cannabinoid-Based Pharmaceuticals Market

The global cannabinoid-based pharmaceuticals market is projected to be valued at $50 billion by 2029 InMed is leading the industry, laying down the foundation in manufacturing and clinical development of rare cannabinoids It is shedding light on the potential of rare cannabinoids and laying the groundwork on how to tap into the industry’s growth It is projected that by 2025, the global cannabis market will be valued at around $146 billion, up from just $20.47 billion in 2020. This sector is experiencing tremendous growth, particularly considering that there are over one hundred known cannabinoids, including rare ones that are quickly…

WednesdayJan 26, 2022 12:00 pm

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) and Lightning Network Could Benefit Immensely by Bitcoin’s Potential as Hedge Against Inflation

Bitcoin is becoming increasingly popular, having already been adopted as legal tender by El Salvador in 2021, and being bartered for incentives in other areas, such as Rio offering a 10% discount when taxes are paid in Bitcoin Instead of spending, some crypto owners (HODLers) are holding crypto in high-yield savings accounts, collecting up to 12% APY interest – benefiting despite the volatility of the coin LQwD has seen exponential growth since its completed acquisition in June 2021, with a current Bitcoin holding of almost 150 tokens Lightning Network has also grown significantly over the past year in terms of…

WednesdayJan 26, 2022 11:45 am

SRAX Inc. (NASDAQ: SRAX) Set to Host the Inaugural Sequire Metals & Mining Conference on January 27, 2022

SRAX will host their inaugural Metals & Mining Conference on January 27, 2022 The conference will be held on Sequire’s Virtual Events platform and will play host to over 70 companies along with a series of industry experts and thought leaders The event marks the latest iteration of SRAX’s extensive conference series, which saw them host the flagship LD Micro Main Event in October 2021 SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has announced that it will be hosting the inaugural Sequire Metals & Mining Conference,…

WednesdayJan 26, 2022 11:30 am

DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF) CryptoHawk Provides Power Predictive Tool to Provide Insight into Volatile Crypto Trading Space

CryptoHawk is designed to monitor, analyze cryptocurrencies to predict price trends and alerts traders when change occurs DIGIMax recently added Altcoin Radar to its CryptoHawk trading tools arsenal to detect unexpected fast rises The world of crypto trading is known for its volatility, with wild fluctuations within the market. DigiMax Global's (CSE: DIGI) (OTC: DBKSF) CryptoHawk, one of the world’s most powerful and complete crypto price prediction indicator tools available, can provide a bird’s eye view of crypto investing, resulting in more efficient predictions (https://ibn.fm/u5jnj). As cryptocurrencies grow in popularity, new investors entering the space will soon find out that…

TuesdayJan 25, 2022 1:00 pm

Microdose Psychedelic Insights to Host Psychedelic Capital Conference

Microdose Psychedelic Insights is a cutting-edge media firm that aims to bring the psychedelics sector to the forefront of contemporary medicine by developing appealing content, disseminating financial analyses, and holding interesting industry events. On January 27, 2022, Microdose will host the Psychedelic Capital January Edition. Attendees will have access to the top firms, most recent IPOs, newest opportunities, and most in-depth market knowledge in the rapidly rising psychedelic medicine sector at the virtual event. Key Points CoveredThis month's conference features dynamic presentations from Heroic Hearts Project, Entheo Digital, PurMinds NeuroPharma, HAVN Life Sciences Inc. and panel discussions on topics of…

TuesdayJan 25, 2022 12:48 pm

Much Maligned Uranium Could Save the Planet

Freakish Midwest tornados, devastating wildfires, extreme droughts, abnormal floods – all signal the onset of a changing global climate. There’s overwhelming concern about climate change, but it’s difficult to achieve consensus on actions to mitigate it. The COP 26 UN Climate Change Conference last November was a step in the right direction, spurring global commitments and serving a clear notice that the era of coal is rapidly coming to an end. Three dozen countries, including the United States, pledged to stop funding fossil fuel projects abroad by the end of this year, and more than 40 countries promised to phase out…

TuesdayJan 25, 2022 12:06 pm

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Reports Findings of Commissioned Study Showing a Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment for Select Mental Conditions

The Harris Poll conducted a survey on behalf of Delic Holdings, polling 2,037 adults ages 18 and older, 953 of whom suffer from anxiety/depression/PTSD The survey revealed that 65% of Americans living with anxiety/depression/PTSD believe that psychedelic medicine should be available to patients with treatment-resistant conditions 66%, 62%, and 56% are open to pursuing ketamine, psilocybin, and MDMA, respectively, to treat anxiety/depression/PTSD if these psychedelic drugs were each proven more effective than prescription medication with fewer side effects Though the U.S. government has not yet federally recognized a medical use for most psychedelic drugs, research by renowned universities and companies…

TuesdayJan 25, 2022 11:14 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Marks Significant Milestone in Pursuit of Berubicin Approval for Global GBM Treatment, Raises $11.5 Million from Private Placement

CNS Pharmaceuticals received approval from swissethics for its potentially pivotal study of Berubicin, a novel anthracycline for the treatment of Glioblastoma Multiforme (“GBM”) The approval is the first from a European Ethics Committee The company, which dosed the first patients in its Berubicin program in September, has selected multiple clinical sites across the U.S., Spain, France, Italy, and Switzerland CNS recently closed an $11.5 million private placement It intends to use the net proceeds to fund its clinical trials and preclinical programs, other R&D programs, and for general corporate purposes Clinical stage biotechnology company CNS Pharmaceuticals (NASDAQ: CNSP) is celebrating…

Site Search

Company Search

Category: Articles